SLAMF7,CS1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CS1,SLAMF7. The page also collects GeneMedi's different modalities and formats products for CS1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CS1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Enables identical protein binding activity. Predicted to be involved in adaptive immune response. Predicted to act upstream of or within regulation of natural killer cell activation. Located in endoplasmic reticulum. [provided by Alliance of Genome Resources, Apr 2022]
|Gene Official Name||SLAMF7|
|Gene Alias||19A, CD319, CRACC, CS1|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Immuno-oncology Target|
Pre-made CS1-specific INN-index biosimilar (antibody&conjugates)-azintuxizumab vedotin, Elotuzumab, Azintuxizumab
Anti-CS1 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-INN-746||Pre-Made Azintuxizumab Vedotin Biosimilar, Whole Mab Adc, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody Drug Conjugate||azintuxizumab vedotin||SLAMF7/CS1||Whole mAb ADC|
|GMP-Bios-ab-172||Pre-Made Elotuzumab biosimilar, Whole mAb, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody||Elotuzumab||SLAMF7/CS1||Whole mAb|
|GMP-Bios-ab-043||Pre-Made Azintuxizumab biosimilar, Whole mAb ADC, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody||Azintuxizumab||SLAMF7/CS1||Whole mAb ADC|
Pre-made anti-CS1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CS1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CS1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T98052-Ab||Anti-CS1/SLAMF7 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|